Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk

Clin Transl Gastroenterol. 2019 Jun;10(6):e00047. doi: 10.14309/ctg.0000000000000047.

Abstract

Introduction: Over the past 20 years, aberrant crypt foci (ACF) have emerged as potential precursors and biomarkers for colorectal cancer (CRC). However, data regarding their molecular pathogenesis, as well as their endoscopic and histological identification, remain inconsistent.

Methods: A wide cohort of ACF from 100 control subjects and 100 case patients, including patients with adenoma and CRC, were characterized for endoscopic, morphologic, and molecular features.

Results: We observed that among all the endoscopic features evaluated, only the number of large ACF correlated with CRC risk (P = 0.003), whereas the histological classification, as assessed by 2 different pathologists, was inconsistent and did not differ between control and case patients. Moreover, only a few APC and BRAF mutations and no microsatellite instability were detected in our samples. KRAS mutations were detected in 16.3% of ACF samples, which also exhibited increased MGMT hypermethylation. However, none of those events were found to be predictive of CRC risk.

Discussion: Although ACF might be preneoplastic lesions of the colon, they are not suitable biomarkers for assessing CRC progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aberrant Crypt Foci / genetics
  • Aberrant Crypt Foci / pathology*
  • Adenoma / diagnosis*
  • Adenoma / pathology
  • Adult
  • Aged
  • Biomarkers
  • Case-Control Studies
  • Colonoscopy
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / pathology
  • DNA Methylation
  • Disease Progression
  • Female
  • Humans
  • Male
  • Microsatellite Instability
  • Middle Aged
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Rectum / pathology*

Substances

  • Biomarkers
  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)